{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:50Z","timestamp":1793183210688,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,10,4]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Cefepime\/enmetazobactam is a novel \u03b2-lactam\/\u03b2-lactamase inhibitor combination and a potential empirical therapy for resistant gram-negative infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate whether cefepime\/enmetazobactam was noninferior to piperacillin\/tazobactam for the primary outcome of treatment efficacy in patients with complicated urinary tract infections (UTIs) or acute pyelonephritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A phase 3, randomized, double-blind, active-controlled, multicenter, noninferiority clinical trial conducted at 90 sites in Europe, North and Central America, South America, and South Africa. Recruitment occurred between September 24, 2018, and November 2, 2019. Final follow-up occurred November 26, 2019. Participants were adult patients aged 18 years or older with a clinical diagnosis of complicated UTI or acute pyelonephritis caused by gram-negative urinary pathogens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Eligible patients were randomized to receive either cefepime, 2 g\/enmetazobactam, 0.5 g (n\u2009=\u2009520), or piperacillin, 4 g\/tazobactam, 0.5 g (n\u2009=\u2009521), by 2-hour infusion every 8 hours for 7 days (up to 14 days in patients with a positive blood culture at baseline).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the proportion of patients in the primary analysis set (patients who received any amount of study drug with a baseline gram-negative pathogen not resistant to either treatment and \u226510<jats:sup>5<\/jats:sup> colony-forming units [CFU]\/mL in urine culture or the same pathogen present in concurrent blood and urine cultures) who achieved overall treatment success (defined as clinical cure combined with microbiological eradication [&amp;amp;lt;10<jats:sup>3<\/jats:sup> CFU\/mL in urine] of infection). Two-sided 95% CIs were computed using the stratified Newcombe method. The prespecified noninferiority margin was \u221210%. If noninferiority was established, a superiority comparison was also prespecified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 1041 patients randomized (mean age, 54.7 years; 573 women [55.0%]), 1034 (99.3%) received study drug and 995 (95.6%) completed the trial. Among the primary analysis set, the primary outcome occurred in 79.1% (273\/345) of patients receiving cefepime\/enmetazobactam compared with 58.9% (196\/333) receiving piperacillin\/tazobactam (between-group difference, 21.2% [95% CI, 14.3% to 27.9%]). Treatment-emergent adverse events occurred in 50.0% (258\/516) of patients treated with cefepime\/enmetazobactam and 44.0% (228\/518) with piperacillin\/tazobactam; most were mild to moderate in severity (89.9% vs 88.6%, respectively). A total of 1.7% (9\/516) of participants who received cefepime\/enmetazobactam and 0.8% (4\/518) of those who received piperacillin\/tazobactam did not complete the assigned therapy due to adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Among patients with complicated UTI or acute pyelonephritis caused by gram-negative pathogens, cefepime\/enmetazobactam, compared with piperacillin\/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological eradication. Further research is needed to determine the potential role for cefepime\/enmetazobactam in the treatment of complicated UTI and pyelonephritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03687255\">NCT03687255<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2022.17034","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:07:07Z","timestamp":1664896027000},"page":"1304","source":"Crossref","is-referenced-by-count":139,"title":["Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis"],"prefix":"10.1001","volume":"328","author":[{"given":"Keith S.","family":"Kaye","sequence":"first","affiliation":[{"name":"Robert Wood Johnson Medical School, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Belley","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, St Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Barth","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, St Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Lahlou","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, St Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Knechtle","sequence":"additional","affiliation":[{"name":"now with discoveric bio beta Ltd, Pf\u00e4ffikon SZ, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Motta","sequence":"additional","affiliation":[{"name":"now with Spexis Ltd, CH-4123 Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Velicitat","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, St Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"joi220102r2","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"joi220102r4","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","article-title":"Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY Antimicrobial Surveillance Program.","volume":"6","author":"Castanheira","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"joi220102r5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jama.2018.12565","article-title":"Carbapenem-sparing therapy for extended-spectrum \u00df-lactamase-producing E coli and Klebsiella pneumoniae bloodstream infection: the search continues.","volume":"320","author":"Hayden","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"joi220102r6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1586\/14787210.6.6.805","article-title":"Cefepime: a reappraisal in an era of increasing antimicrobial resistance.","volume":"6","author":"Endimiani","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"joi220102r7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jgar.2021.02.031","article-title":"Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of \u00df-lactamases and comparative in vitro activity of cefepime\/enmetazobactam.","volume":"25","author":"Belley","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"joi220102r8","doi-asserted-by":"crossref","first-page":"S539","DOI":"10.1093\/ofid\/ofz360.1341","article-title":"A randomized phase 2 study of cefepime combined with the novel extended spectrum \u00df-lactamase inhibitor enmetazobactam in hospitalized adults with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP).","volume":"6","author":"Carmeli","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"joi220102r13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00514-19","article-title":"In vitro activity of cefepime-enmetazobactam against gram-negative isolates collected from United States and European hospitals during 2014-2015.","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"joi220102r14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"3","key":"joi220102r16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab045","article-title":"Heterogeneity of recent phase 3 complicated urinary tract infection clinical trials.","volume":"8","author":"Portsmouth","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"joi220102r17","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/AAC.00607-13","article-title":"Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae.","volume":"57","author":"McLaughlin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"joi220102r18","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum \u00df-lactamases: an update on their characteristics, epidemiology and detection.","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"5","key":"joi220102r20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u00df-lactam-\u00df-lactamase inhibitor combination.","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"joi220102r21","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial.","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"joi220102r22","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2\/3 randomized trial.","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"joi220102r3","volume-title":"Antibiotic Resistance Threats in the United States","author":"Centers for Disease Control and Prevention, National Center for Emerging Zoonotic and Infectious Diseases, Division of Healthcare Quality Promotion, Antibiotic Resistance Coordination and Strategy Unit","year":"2019"},{"key":"joi220102r9","author":"Motta"},{"key":"joi220102r19","volume-title":"Global Priority List of Antibiotic-Resistant Bacteria To Guide Research: Discovery and Development of New Antibiotics","author":"World Health Organization","year":"2017"},{"key":"joi220102r1","unstructured":"Pfizer. ZOSYN full prescribing information. Accessed May 17, 2021. https:\/\/labeling.pfizer.com\/showlabeling.aspx?format=PDF&id=1177"},{"key":"joi220102r10","unstructured":"US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research. Complicated urinary tract infections: developing drugs for treatment: guidance for industry. June 2018. Accessed September 10, 2018. https:\/\/www.fda.gov\/media\/71313\/download"},{"key":"joi220102r11","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. December 19, 2018. Accessed July 21, 2021. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf"},{"key":"joi220102r12","unstructured":"Food and Drug Administration. Collection of race and ethnicity data in clinical trials: guidance for industry and Food and Drug administration staff. October 26, 2016. Accessed April 15, 2022. https:\/\/www.fda.gov\/media\/75453\/download"},{"key":"joi220102r15","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. May 19, 2022. Accessed July 18, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf"},{"key":"joi220102r23","unstructured":"Tamma? PD, Aitken? SL, Bonomo? RA, Mathers? AJ, van Duin? D, Clancy? CJ. IDSA guidance on the treatment of antimicrobial-resistant gram-negative infections: version 1.0. March 7, 2022. Accessed April 19, 2022. https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/#"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2796946\/jama_kaye_2022_oi_220102_1664214329.07421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:07:19Z","timestamp":1664896039000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2796946"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,10,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.17034","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}